ATE334690T1 - Zusammensetzungen zur behandlung von bindegeweben,die ein eisen(ii)-ion und ascorbat enthalten - Google Patents

Zusammensetzungen zur behandlung von bindegeweben,die ein eisen(ii)-ion und ascorbat enthalten

Info

Publication number
ATE334690T1
ATE334690T1 AT01927527T AT01927527T ATE334690T1 AT E334690 T1 ATE334690 T1 AT E334690T1 AT 01927527 T AT01927527 T AT 01927527T AT 01927527 T AT01927527 T AT 01927527T AT E334690 T1 ATE334690 T1 AT E334690T1
Authority
AT
Austria
Prior art keywords
ascorbate
treatment
compositions
connective tissue
ferric ion
Prior art date
Application number
AT01927527T
Other languages
English (en)
Inventor
V Ekanayake
Original Assignee
Ocean Nutrition Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocean Nutrition Canada Ltd filed Critical Ocean Nutrition Canada Ltd
Application granted granted Critical
Publication of ATE334690T1 publication Critical patent/ATE334690T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Removal Of Specific Substances (AREA)
AT01927527T 2000-04-28 2001-04-25 Zusammensetzungen zur behandlung von bindegeweben,die ein eisen(ii)-ion und ascorbat enthalten ATE334690T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20036100P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
ATE334690T1 true ATE334690T1 (de) 2006-08-15

Family

ID=22741396

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927527T ATE334690T1 (de) 2000-04-28 2001-04-25 Zusammensetzungen zur behandlung von bindegeweben,die ein eisen(ii)-ion und ascorbat enthalten

Country Status (8)

Country Link
US (1) US6632804B2 (de)
EP (1) EP1276485B1 (de)
JP (1) JP2003531858A (de)
AT (1) ATE334690T1 (de)
AU (1) AU2001254556A1 (de)
CA (1) CA2343439C (de)
DE (1) DE60121932D1 (de)
WO (1) WO2001082938A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851458B2 (en) * 1999-06-22 2010-12-14 Joint Juice, Inc. Cartilage enhancing food supplements and methods of preparing the same
ES2190379B1 (es) * 2001-12-21 2004-11-16 Bioiberica,S.A Procedimiento de preparacion de sales de glucosamina.
US20080003258A1 (en) * 2002-10-16 2008-01-03 Marcum Frank D Composition and Method for Treating Rheumatoid Arthritis
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
US7803787B2 (en) * 2002-10-16 2010-09-28 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage by transmucosal administration
US20040086581A1 (en) * 2002-11-06 2004-05-06 Jones Edwin B. Bio-energetic joint and arthritis pain formula
CN1232256C (zh) * 2003-03-27 2005-12-21 中国人民解放军第三军医大学 N－乙酰氨基葡萄糖在制备治疗自身免疫反应所致的局部损伤或全身症状的药物中的应用
US8633247B2 (en) * 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
US8633246B2 (en) * 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
ES2255829B1 (es) * 2004-08-06 2007-08-16 Bioiberica, S.A. Nuevo uso de sales de glucosamina.
CA2603518C (en) * 2005-04-13 2013-11-26 Snow Brand Milk Products Co., Ltd. Nutrient composition for promoting collagen production
DE102005020327A1 (de) 2005-04-30 2006-11-09 Multibind Biotec Gmbh Dekontaminationslösungen und deren Verwendung zur Denaturierung, Modifikation, Degradation, Solubilisierung und Entfernung von Proteinen, Nukleinsäuremolekülen und Mikroorganismen von Oberflächen
DE102006001213A1 (de) * 2006-01-10 2007-07-12 Multibind Biotec Gmbh Synergistische Lösung aus Ascobinsäure oder deren Derivaten und Metallionen effizienten, selektiven Abtötung pathologischer Säugerzellen
US9089156B2 (en) * 2006-06-05 2015-07-28 Stokely-Van Camp, Inc. Reducing muscle soreness with glucosamine compositions
US9186375B2 (en) 2007-06-21 2015-11-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan compositions in combination with stem cells
BE1019135A5 (nl) * 2010-01-08 2012-03-06 Lab Smeets Nv Voedingssupplement bevattende glucosamine.
US10143219B2 (en) * 2013-03-06 2018-12-04 Rutgers, The State University Of New Jersey Nutritional supplement/feed formula and methods of use thereof to reduce development of Osteochondrosis Dissecans (OCD) lesions
EP2886104A1 (de) 2013-12-11 2015-06-24 Patir, Suleyman Intraartikuläres Gel
WO2017116273A1 (en) * 2015-12-30 2017-07-06 Asafov Alexander Vilenovich Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2822317A (en) * 1955-12-12 1958-02-04 Smith Kline French Lab Aqueous iron-ascorbic acid preparation
IT1044707B (it) 1968-10-26 1980-04-21 Rotta Research Lab Procedimento per la preparazione di sali di glucosanina e preparati farmaceutici comprendenti detti sali di glucosamina come agenti attivi
NZ194947A (en) 1979-09-18 1983-06-14 C Holland Composition containing calcium and ferrous ions for treatment of rheumatoid arthritis
WO1985000033A1 (en) * 1983-06-18 1985-01-03 Japan As Represented By Director-General Of Agency Chemically active aqueous solution and solid substance containing ferrous ion
US5405613A (en) * 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
US5364845C1 (en) 1993-03-31 2002-09-10 Nutramax Lab Inc Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue
AT408416B (de) * 1996-07-19 2001-11-26 Norbert Fuchs Pharmazeutische bzw. diätetische zusammensetzungen
GB2317109B (en) 1996-08-28 2000-06-21 Farmsense A therapeutic composition for the treatment and repair of connective tissue in mammals
GB9621273D0 (en) 1996-10-11 1996-11-27 Cortecs Ltd Therapeutic method
US6245360B1 (en) * 1998-06-26 2001-06-12 John S. Markowitz Nutritional supplement
US6177476B1 (en) * 1998-08-27 2001-01-23 Clarion Pharmaceuticals Inc. Nutritional supplements for replenishing plasmalogens
DE20004010U1 (de) * 2000-03-02 2000-06-21 Febena Pharma GmbH, 50825 Köln Diätische Zusammensetzung mit einem Gehalt an Glycosaminoglycanen

Also Published As

Publication number Publication date
EP1276485A2 (de) 2003-01-22
US20010044425A1 (en) 2001-11-22
CA2343439C (en) 2003-06-24
JP2003531858A (ja) 2003-10-28
DE60121932D1 (de) 2006-09-14
EP1276485B1 (de) 2006-08-02
WO2001082938A2 (en) 2001-11-08
US6632804B2 (en) 2003-10-14
CA2343439A1 (en) 2001-07-09
WO2001082938A3 (en) 2002-08-08
AU2001254556A1 (en) 2001-11-12

Similar Documents

Publication Publication Date Title
ATE334690T1 (de) Zusammensetzungen zur behandlung von bindegeweben,die ein eisen(ii)-ion und ascorbat enthalten
IL164509A0 (en) Furyl compounds
IS6852A (is) Efnasambönd
UA89040C2 (ru) Замещенные глюкопиранозилом бензольные производные, лекарственное средство, которое содержит эти соединения
TNSN05278A1 (en) Inhibitors of phosphatidylinositol 3-kinase
IL172773A (en) Formulations for the treatment of arthritis conditions
IL164613A0 (en) Thienyl compounds
PL362274A1 (en) Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
MXPA04006255A (es) Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
TNSN08057A1 (en) Combinations comprising dmxaa for the treatment of cancer
GEP20053590B (en) Phenyl Heterocyclyl Ether Derivatives as Serotonin Re-Uptake Inhibitors
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
MXPA05007715A (es) Derivados de carboxamida y uso de los mismos como inhibidores del factor xa.
AU2001276437A1 (en) Use of polysulphated cyclodextrins for treating osteoarthritis
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
ATE397003T1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren
BR0112268A (pt) Composto de metaciclina 13-substituìda, método para tratar um estado responsivo a tetraciclina em um mamìfero, composição farmacêutica, e, método papa sintetizar um composto de metaciclina 13-substituìda
DE60301496D1 (de) Zusammensetzung zur topischen behandlung von vulvovaginitis und mykosen
WO2001025264A3 (en) Substituted phosphinate based peptide derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties